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 Dose escalation using contact x-ray brachytherapy (Papillon) for rectal 
cancer. Does it improve the chance of organ preservation? 
  
Abstract 
Objectives 
A watch and wait policy for patients with a complete clinical response (cCR) after external 
beam chemoradiotherapy (EBCRT) for rectal cancer is an attractive option. However, 
approximately a third of tumours will regrow, which requires surgical salvage for cure. We 
assessed whether contact x-ray brachytherapy (CXB) can improve organ preservation by 
avoiding surgery for local regrowth. 
Methods 
From our institutional database, we identified 200 of 573 patients treated by CXB from 2003 
to 2012. Median age was 74 years (range 32–94), and 134 (67%) patients were men. 
Histology was confirmed in all patients and was staged using CT scan, MRI, or endorectal 
ultrasound. All patients received combined CXB and EBCRT, except 17 (8.5%) who had 
CXB alone.  
Results 
Initial cCR was achieved in 144/200 (72%) patients. 38/56 (68%) patients who had residual 
tumour received immediate salvage surgery. 16/144 (11%) patients developed local regrowth 
after cCR, and 124/144 (86%) maintained cCR. At median follow up of 2.7 years, 161 
(80.5%) patients were free of cancer. The main late toxicity was bleeding (28%). Organ 
preservation was achieved in 124/200 (62%) patients.  
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Conclusion 
Our data suggest that CXB can reduce local regrowth to 11% compared with around 30% 
after EBCRT alone. Organ preservation of 62% achieved was higher than reported in most 
published watch and wait studies.  
Advances in knowledge  
CXB is a promising treatment option to avoid salvage surgery for local regrowth, which can 
improve the chance of organ preservation in patients who are not suitable for or refuse 
surgery. 
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Introduction 
Patients often prefer not to have surgery if they have a choice.1 Therefore, a watch and wait 
policy for responders after external beam chemoradiotherapy (EBCRT) is gaining acceptance 
as an alternative to radical surgery in patients with rectal cancer, since it avoids extirpative 
surgery and a stoma.2 However, published evidence suggests that local regrowth occurs in up 
to a third of patients despite them having achieved an initial clinical complete response 
(cCR).3 Most patients who are fit and agreeable for surgery have salvage operations for local 
regrowth, which reduces their overall chance of organ preservation to less than 40%.3,4 There 
is a need to investigate methods to reduce local regrowth rates. One approach is to offer 
contact x-ray brachytherapy (CXB) after external beam radiotherapy (EBRT) or external 
beam chemoradiotherapy (EBCRT).5,6 We report our experience in a real-world situation in 
patients who were either not suitable for surgery or were fit but refused surgery and were 
referred to our centre for non-surgical treatment. We offered CXB to this group of patients to 
avoid salvage surgery for local regrowth and to improve their chance of organ preservation. 
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Materials and methods 
We identified 200 consecutive patients with operable rectal cancer from our institutional 
database of 573 patients who had been referred to our centre from January 1, 2003, to 
December 31, 2012. CXB was offered with the intent of reducing local regrowth to avoid 
salvage surgery in patients who were not suitable for or refused surgery within the study 
period. The selection and exclusion criteria are shown in Table 1. Histological diagnosis was 
confirmed in all patients. Baseline pre-treatment assessment included endoscopy, digital 
rectal examination (DRE), MRI, CT scan, and endorectal ultrasound (if MRI was not possible 
due to cardiac pacemaker), and was undertaken at the patients’ local referring centres. Pre-
treatment stages cT1–cT4 and cN stages (AJC/UICC v7) are shown in Table 2. All patients 
were discussed at their local colorectal multidisciplinary team meetings before referral.  
Seventeen patients presenting with rectal cancers of 3 cm or smaller (cT1 or cN0; mainly 
adenomas with small focus of cancer) were referred for consideration for CXB upfront 
because they were not suitable for surgery (n=17). All other patients who had advanced 
tumours larger than 3 cm in diameter (cT2 or cT3/cN1/cN2) had EBRT/EBCRT locally to 
downsize and downstage their tumours. Our proposed treatment algorithm is shown in 
Figure 1.  All patients had repeat endoscopy, DRE, and restaging scans to assess their 
response to EBRT/EBCRT (usually within 6-8 weeks). They were then discussed again at 
their local multidisciplinary team meeting, and surgery was offered to all with residual 
disease, since this was ‘the standard of care’. However, those patients who were not suitable 
for surgery or those who were fit but refused surgery were referred to us for consideration of 
CXB boost.  
Our study was a retrospective observational audit approved by the audit committee (01-
02/26). All patients agreed to CXB after a full explanation that this treatment might not be 
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curative, and that they may need future salvage surgery if there was a residual tumour or local 
regrowth, provided that they were fit and agreeable for surgery (Figure 2).  
Exclusion criteria 
We excluded all patients where we could not locate the area to treat with CXB boost after 
EBRT/EBCRT. They were offered the watch and wait protocol and followed up locally. 
Some of those patients who were referred were also found to have a bulkier residual tumour 
at endoscopy (>3 cm) and were instead offered high-dose-rate endoluminal brachytherapy 
using a rectal applicator (Elekta, Stockholm, Sweden). The decision not to treat residual 
tumours larger than 3 cm was because the largest rectal applicator that we can use for CXB is 
30 mm. These patients were also excluded from our study (n=46). Patients (n=180) who had 
initial excision of tumour by TEMS (transanal endoscopic microsurgery), TART (transanal 
resection of tumour), or EMR (endoscopic mucosal resection) were also excluded. In 
addition, patients who had tumour regrowth after EBRT/EBCRT and those with metastatic 
disease were treated palliatively with CXB (n=86), and were excluded from our analysis. 
Sixty-one (10.6%) patients with missing data were also excluded (Figure 2).  
External beam radiotherapy 
All patients received EBRT/EBCRT except those with polyp cancer of 3 cm or smaller (cT1 
cN0; n=17). Patients who were fit for treatment had 45 Gy in 25 fractions over 5 weeks with 
5-fluorouracil 1 g/m2 (days 1–4 in weeks 1 and 5) or oral capecitabine 825 mg/m2 twice a day 
on the days of radiation (n=127). Patients with poor renal function received EBRT without 
chemotherapy (n=56). 
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Contact x-ray brachytherapy (Papillon) 
Since 2009, CXB was delivered using a Papillon 50 machine (Ariane, Derby, UK; Figure 3). 
However, a Therapax machine (Gulmay, Surrey, UK) was used between 1993 and 2009. The 
details of the CXB treatment schedule, set up, and data comparing the two machines has been 
described in our earlier publications.6–8 CXB was administered as outpatient treatment every 
2 weeks. A surface dose of 30 Gy using 50 kVp X-rays (HVL 0.64 Al, 2.7 mA) was delivered 
through a rectal treatment applicator at each visit. The size of treatment applicator (30, 25, or 
22 mm) was chosen to cover the tumour with a 5-mm margin, and was targeted under direct 
visual guidance (Figure 4). Most patients received no more than a total dose of 90 Gy 
delivered in three fractions every 2 weeks for 4 weeks.6–8  
Surveillance protocol  
Close follow-up was done within the first 2 years, when the risk of tumour recurrence was 
highest. During this period, patients were seen every 3 months for digital rectal examination 
(DRE) and sigmoidoscopy. MRI and CT scans were done every 4–6 months. A clinical 
complete response (cCR) was defined as a complete absence of palpable, endoscopic, or 
radiological evidence of a residual tumour.3,4,9 If there was a progressive suspicious mucosal 
abnormality detected endoscopically, or if progressive induration was felt on DRE, patients 
were referred for immediate salvage surgery provided they were fit and willing to accept this 
treatment.3,4 Isolated subtle abnormalities on the MRI scan or mucosal abnormalities on 
endoscopy that did not change or progress over time were regarded as static disease and kept 
under review. 
All patients with a sustained cCR on the watch and wait pathway after CXB were reassessed 
every 6 months after the first 2 years, alternating with their referring clinician from their local 
hospitals for up to 5 years. If any active regrowth of the tumour was detected after an initial 
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cCR, the patient was restaged and offered delayed surgical salvage, provided no inoperable 
distant metastases were present and that the patient was fit and agreeable for surgery (Figure 
2). We encouraged clinicians not to biopsy the scar if no obvious cancer remained, due to the 
known low negative predictive value of negative histology. Scarring or ulceration resulting 
from biopsy could also make subsequent endoscopic and MRI appearances difficult to 
interpret.10, 11  
Statistical analysis 
Our main objective was to demonstrate the effectiveness of CXB in reducing local regrowth 
in our cohort, which have shown to improve the chance of organ preservation by avoiding 
salvage surgery. The overall survival, local progression free survival, and the disease-free 
survival, were estimated using the Kaplan-Meier survival methodology. Univariate and 
multivariate analyses using logistic regression were done to identify factors associated with 
initial response and local regrowth (Table 3). Additionally, Cox regression analysis was done 
to identify factors associated with disease-free survival (Table 4). An external independent 
validator was commissioned to ensure the accuracy and integrity of our data, since it had 
been accrued over many years. This process indicated that 94% of initial data entries were 
accurate. Data were analysed using SPSS Version 21 (IBM, Portsmouth, UK). 
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Results  
Patient characteristics 
Our institutional database identified 200 patients who had been diagnosed with either rectal 
polyp cancer ≤3 cm (cT1/cN0) or residual rectal cancer measuring ≤3 cm after 
EBRT/EBCRT (cT2, cT3a, cN0, cN1). There were 3 patients with cT4 tumours but all were 
down staged with minimal residual tumour prior to CXB boost. The baseline demographics 
of our patients are shown in Table 2 and their outcomes are summarised in Figure 2.  
Complete clinical response  
An initial cCR was seen in 144 (72 %) of 200 patients following CXB. Examples of 
responses to CXB for early stage tumour (≤3 cm) followed by EBCRT and for more 
advanced tumours (>3 cm) treated with initial EBRT or EBCRT followed by CXB boost are 
shown in Figures 5 and 6. Univariate logistic regression analysis did not identify any 
prognostic factors related to the initial response (Table 3).  
Incomplete clinical response 
Despite the high dose received from CXB, 56 (28%) of 200 patients had an incomplete 
clinical response. This finding suggests that inherent tumour radio-resistance plays an 
important role. 38 patients (68%) from within this group subsequently underwent immediate 
salvage surgery. Of these patients, eight (21%) had no pathological evidence of residual 
disease (ypT0). Sixteen patients did not proceed to surgery due to advanced age and 
comorbidities, and two other patients refused surgery.  
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Local regrowth after initial complete clinical response  
At the study cut-off date, 16 (11%) of the 144 patients who initially achieved cCR developed 
a local regrowth. The median time for this to occur was 16 months (range 4.0–113). 
Univariate analysis using logistic regression did not identify any prognostic factors associated 
with local regrowth (Table 3). 
Local regrowth management 
Of the 16 patients who developed a local regrowth, three had distant metastases in addition to 
local regrowth. Ten (77%) of 13 patients with salvageable local and regional regrowth 
underwent delayed salvage surgery.12 Importantly, two of the ten patients (20%) who 
underwent salvage surgery for suspected local regrowth seen endoscopically had a 
pathological stage of ypT0.  
Distant metastases  
Of the 200 patients in this study, 17 (8.5%) developed metastatic disease. Four patients had 
lung resections for their metastatic disease, and the others received symptomatic palliative 
care only due to their advanced age or comorbidities. 
Disease-free survival  
The Kaplan-Meier probabilities of disease-free survival for the whole group were 72% (95% 
CI 66–78) at 2 years, 65% (95% CI 58–72) at 3 years, and 53% (95% CI 44–62) at 5 years 
(Figure 7). Cox regression analysis was carried out to identify factors associated with disease-
free survival (Table 4). Performance status, age at presentation, and treatment modality were 
found to be significant factors for the disease-free survival. The local progression-free 
survival and overall survival for the corresponding periods were also estimated using the 
Kaplan-Meier probabilities (Figures 8 and 9). This outcome highlights the elderly nature of 
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our patients who also had medical comorbidities, and many died from other causes unrelated 
to their cancer.  
Toxicities  
CXB was well tolerated and no patient had to stop treatment because of gastrointestinal 
toxicity. Rectal ulceration (grade 1) developed in 30% of patients after receiving CXB, but 
this usually healed within 3–6 months. Fifty-six patients (28%) developed bleeding (grade 1) 
due to telangiectasia, and 21 patients (10.5%) needed argon beam therapy (grade 2) for 
haemostasis (Common Toxicity Criteria Score v4.0).13, 14 No patients needed colostomy due 
to late gastrointestinal toxicity (grade 3). No deaths were reported related to CXB. 
Outcomes 
At the end of study period, with a median follow-up of 2.7 years, 161 (80.5%) of 200 patients 
were alive and free from cancer, including those patients who had salvage surgery (Figure 2). 
22 (11%) of the 200 patients had progressive local disease, and 17 (8.5%) developed distant 
metastases. Organ preservation with no residual tumour was achieved in 124 (62 %) of 200 
patients. Of the 136 patients who remained alive, 108 (79.4%) were colostomy-free.  
  
Discussion 
Our data show that we achieved organ preservation in 124 (62%) of 200 patients, which was 
much higher than in most other published series.3, 4 One hundred and eight (78.6%) out of 
136 patients who were alive at the end of our study period were also colostomy-free. 
Organ preservation has been achieved with a non-surgical approach using radiation in rectal 
cancer for many years.15 Jean Papillon from Lyon advocated the use of non-surgical 
treatment with CXB for operable rectal cancer in elderly patients, and popularised the 
12 
 
radiation technique that bears his name.15 Papillon treated 312 patients and achieved local 
control in 91% of cases. His protégé Jean Pierre Gerard continued championing contact x-ray 
brachytherapy (Papillon) in Lyon and later moved to Nice. He had published many scientific 
papers including the randomised trial Lyon 96-02.16, 17 Ben Sischy visited Lyon in the early 
seventies, and then started a CXB facility in the USA. He was able to replicate both 
Papillon’s and Gerard’s results with local control of 95% in his cohort of 227 patients.18 WM 
Mendenhall and colleagues from Florida also reported their results on patients with rectal 
cancer treated by CXB.19 There have also been several publications on its efficacy from the 
UK.6,7 In France, HAS (Haute Autorité de Santé) has officially recommended CXB for rectal 
cancer since October 2008,20 and in the UK, NICE (National Institute for Health and Care 
Excellence) has recommended CXB for patients with early rectal cancer who are not suitable 
for surgery since September 2015.21  
The published evidence suggests that EBRT alone can achieve pathological complete 
response in about 30–40% of cases if surgery was deferred up to 10 weeks. However, 
residual disease was still present in 60–70% of cases.22, 23 Investigators in a Brazilian study4 
were one of the first groups to publish the concept of watch and wait in 183 patients who had 
been treated with EBCRT, and showed 90 (49%) cases achieved cCR. However, at median 
follow-up of 60 months, 28 (31%) patients developed local regrowth within the first two 
years.4 Twenty-six patients had salvage surgery. In total, seventy patients had organ 
preservation, as some of patients who had surgical salvage had local excision for their 
recurrences. Therefore, 70 (38%) of 183 patients achieved organ preservation at the end of 
their treatment. In our study, 124 (62 %) of 200 patients achieved organ presentation, which 
is much higher than that reported by the Brazilian group. Comparable group to our cohort 
who achieved cCR treated with EBRT alone was reported by Renehan’s group which showed 
local regrowth of 38%.3 To reduce this local regrowth, the authors of a Danish study used 
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brachytherapy 5 Gy at 10 mm depth to escalate the dose after an initial high dose of 60 Gy 
EBCRT using intensity modulated radiotherapy (IMRT) with in-field boost technique. 
Although there was a higher initial response in 40 (78%) of 51 patients, 25.9% of their 
patients still developed local regrowth within 2 years.24 The Danish group modelled a 
predictive dose response curve to explain their failure and found that the radiation dose 
needed to sterilise the tumours (D50) was 92 Gy (95% CI 79–145; Figure 10). This dose is 
not possible to achieve with EBRT even using modern technology such as stereotactic body 
radiotherapy (SBRT).25  
One elegant way to improve the dose delivered to the tumour is by CXB, which can be used 
to escalate the dose up to 90 Gy in addition to the initial EBRT dose of 45 Gy. At each 
application of 30 Gy, every 2 weeks, layer by layer the tumour is shaved off from the top 
until it reaches its base (at the end of treatment) in responders.26 Although the dose of 90 Gy 
seems quite high, most of the dose is deposited within a small treatment volume (5 mL) that 
is applied directly to the tumour. In addition, due to its low energy (50 kVp) and short focal 
surface distance (FSD), the penetration into the tissues is limited, which spares the normal 
tissues around the tumour.26, 27 
The published evidence on the combination of EBRT with CXB in two prospective studies 
has shown that local regrowth rates can be significantly reduced. Data from a UK study 
showed reduced local regrowth of 12% at 2 years,28 and data from a French study also 
predicted a reduction in local regrowth to 11% at 5 years.29 Both series reported similar 
results to our study (11% local regrowth at 2.7 years). Therefore, we postulate that CXB 
plays a significant part in reducing the likelihood of local regrowth. The reasoning behind 
this postulate is that the additional high dose of focused radiation using CXB to a small 
targeted area enables eradication of residual nests of tumour cells that lie at the base of the 
tumour beneath the rectal mucosa.27 There was additional evidence to support this hypothesis 
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from a randomised trial (Lyon 96-02), which showed improved clinical (24% vs 2%) and 
pathological response (57% vs 34%) in favour of a CXB boost in addition to EBRT alone.16  
We accept that there were several limitations to our study. Our study was not randomised and 
was merely a retrospective audit of patients who had been treated over many years, with all 
the drawbacks associated with such a retrospective study. The follow-up period was short, 
and we do not know the exact number of patients who had EBRT/EBCRT but were not 
referred to our centre for CXB boost. We hope to address these limitations with the European 
multicentre prospective randomised trial (OPERA), which is on-going and which will assess 
the role of CXB boost in addition to EBCRT. This study is registered with ClinicalTrials.gov, 
number NCT02505750. Organ preservation at 3 years will be the primary endpoint.30 
 
Conclusion  
Our data showed that when CXB was used alone for small rectal cancer or as a boost in 
combination with EBRT/EBCRT for more advanced rectal tumours, it could reduce local 
regrowth rates. Therefore, CXB can be considered as a viable treatment option to reduce local 
regrowth in patients with rectal cancer who are not suitable for salvage surgery or who are fit 
but refuse surgery because they are stoma averse. This option could improve their chance of 
organ preservation by avoiding surgical salvage and a stoma. 
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Table 1 
 Inclusion criteria for CXB 
1. Histologically proven rectal cancer. 
2. Well to moderately well differentiated adenocarcinoma. 
3. Stage T1-3 mobile tumour less than 3cm in size. Any N stage within the mesorectum. 
4. Tumour situated less than 12 cm from the anal verge. 
5. Patients must be suitable for long term follow up. 
 
 Exclusion criteria for CXB 
1. Poorly differentiated adenocarcinoma. 
2. Presence of lympho-vascular invasion. 
3. Size (largest) of tumour more than 3 cm or over half the circumference of the rectal lumen. 
4. Any lymph node outside the mesorectum. 
5. Presence of proven distant metastases. 
6. Local regrowth after achieving cCR following EBCRT. 
7. Previous surgical excision of tumour. 
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Table 2:  Baseline characteristics   
  N  % 
Age in years, 
median (range) 
 74 (32–94) .. 
Sex Women 66 33.0% 
Men 134 67.0% 
Performance status 0 66 33.0% 
1 73 36.5% 
2 41 20.5% 
3 7 3.5% 
Not known 13 6.5% 
Differentiation Well 10 5.0% 
Moderate 121 60.5% 
Poor 6 3.0% 
Not known 63 31.5% 
Tumour stage 
(pre-treatment) 
cT1 21 10.5% 
cT2 89 44.5% 
cT3 87 43.5% 
cT4 3 1.5% 
Nodal stage cN0 125 62.5% 
cN1 56 28.0% 
cN2 18 9.0% 
Not known  1 0.5% 
Metastases stage M0 200 100% 
 
Distance from anal 
verge 
<7 cm 144 72.0% 
7–11 cm 47 23.5% 
>11 cm 2 1.0% 
Not recorded 7 3.5% 
Tumour size 
≤3 cm 107 53.5% 
 >3 cm 65 32.5% 
 Not recorded 28 14.0% 
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Table 3: Prognostic factors on response and regrowth 
 
 
 
 
Treatment response Local regrowth 
 
 
N HR 95% CI p HR 95% CI p 
PS  0 66 Ref  0.15 Ref  0.83 
1 73 0.43 0.20–0.95 1.30 0.39–4.29 
2 41 0.93 0.40–2.13 2.09 0.59–7.35 
3  7 0.80 0.14–4.46 0.00 0.00 
Not known 13 1.71 0.51–5.72 1.02 0.11–9.49 
Age group <70 72 Ref  0.26 Ref  0.46 
70–79 63 0.48 0.22–1.02 1.41 0.41–4.87 
80–89 57 0.60 0.60–2.78 1.58 0.46–5.46 
≥90  8 0.00 0.00 4.47 0.71–28.13 
Tumour stage  cT1 21 Ref  0.20 Ref  0.90 
cT2 89 1.23 0.37–4.08 0.59 0.14–2.46 
cT3 87 2.35 0.73–7.61 0.61 0.15–2.52 
cT4  3 2.12 0.15–29.66 0.00 0.00 
Nodal stage  Negative 125 Ref  0.59 Ref  0.63 
Positive 74  1.344 0.72–2.62 1.59 0.61–4.12 
Not known  1 0.00 0.00 0.00 0.00 
Distance from anal verge <7 cm 144 Ref  0.88 Ref  0.91 
7–11 cm 47 1.07 0.52–2.20 0.46 1.47–0.53 
>11 cm 2 0.00 0.00 0.00 0.00 
Not known 7 0.42 0.05–3.59 0.00 0.00 
Tumour size ≤ 3 cm 107 Ref  0.28 Ref  0.50 
>3 cm   65 1.56 0.79–3.11 0.80 0.29–2.26 
Not known   28 1.82 0.75–4.45 0.29 0.04–2.36 
Treatment method Chemoradiation 127 Ref  0.20 Ref  0.50 
EBRT alone   56 0.51 0.24–1.01 1.03 0.34–3.13 
CBX alone  17 0.64 0.20–2.10 2.26 0.56–9.09 
Papillion total dose ≤90 Gy 162   0.40 Ref  0.20 
>90 Gy   32 0.68 0.28–1.67 2.04 0.68–6.12 
PS=performance status.; EBRT= external beam radiotherapy; CXB=contact x-ray brachytherapy.  
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Table 4: Relationship of disease-free survival to prognostic factors 
 
Prognostic factors 
N 
Disease-free 
survival at 
median time 
of follow up 
Univariate analysis Multivariate analysis 
HR 95% CI p HR 95% CI p 
Performance 
status 
0 66 76%   <0.001    
1 73 74% 1.21 0.69-2.14     
2 41 35% 2.73 1.51-4.96     
3 9 38% 3.79 1.41-10.17     
Not known 13 77% 0.52 0.19-1.39     
Age group 
(years) 
<70 72 80%   <0.001   <0.001 
70-79 63 75% 1.39 0075-2.58  1.39 0.75-2.58  
80-89 57 42% 4.39 2.47-7.80  4.39 2.47-7.80  
≥90 8 50% 3.15 1.24-8.00  4.15 1.24-8.00  
Tumour 
stage  
cT1 21 70%   0.79    
cT2 89 72% 1.31 0.62-2.80     
cT3 87 59% 1.46 0.67-3.17     
cT4 3 67% 0.97 0.12-7.78     
Nodal stage  Negative 125 69%   0.99    
Positive 74 62% 1.01 0.63-1.62     
Not known 1 - 0.00 0.00     
Distant from 
anal verge 
<7 cm 144 68%   0.28    
7-11 cm 47 59% 1.47 0.92-2.33     
>11 cm 2 - 1.43 0.20-10.38     
Not known 7 71% 0.53 0.13-2.17     
Tumour size ≤3cm 107 72%   0.44    
>3cm 65 60% 1.33 0.83-2.13     
Not known 28 59% 1.29 0.71-2.36     
Treatment 
modality 
RT alone 127 54%   0.002    
Chemo-
radiation 
56 71% 2.27 1.44-3.56     
CXB alone 17 71% 1.47 0.69-3.14     
Papillion 
total dose 
≤90 Gy 168 66%   0.70    
>90 Gy 32 64% 1.11 0.65-1.92     
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Figure 7 
 
  
   
  
  
Time   DFS (95% CI)   
 year 2   %  (66 72 – 78 % )   
3 year   65 %  (58 – 72 % )   
5 year   53 %  (44 – % ) 62   
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Figure 8 
 
  
  
  
  
  
  
  
   
  
  
Time   local progression  
free survival    (95 % CI )   
 year 2   74 %  (68 – 80 % )   
3 year   %  (59 66 – 73 % )   
 year 5   52 %  (43 – 61 % )   
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Figure 9 
 
  
 
  
Time   Overall Survival  (95% CI)   
 year 2   %  (83 88 - 93 % )   
3 year   82 %  (76 - 88 % )   
5 year   64 %  (55 - % ) 73   
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Figure 10 
           95% CI 79-145  
  
 
  
  
  
  
   
 
  
